DiaMedica Therapeutics Inc. (DMAC)
DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.
Address
301 CARLSON PARKWAY
MINNEAPOLIS, MN 55305
Founded
2000
Number of Employees
19
Website
http://www.diamedica.com
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)